Literature DB >> 33723737

Bone and joint infections caused by Clostridium perfringens: a case series.

Margaux Visse1, Véronique Vernet-Garnier2, Odile Bajolet3, Delphine Lebrun4, Morgane Bonnet5, Maxime Hentzien1, Xavier Ohl6, Saidou Diallo6, Firouzé Bani-Sadr7.   

Abstract

The objective of this study was to evaluate antimicrobial therapy outcomes of bone and joint infections (BJI) caused by Clostridium perfringens. We investigated remission of symptoms and the absence of relapse or reinfection during follow-up. Among the 8 patients with C. perfringens BJI, the type of infection was early prosthesis infection (n = 2), osteosynthetic device infection (n = 4), and chronic osteomyeletis (n = 2). Clindamycin-rifampicin combination was given in 4 cases and metronidazole in 4 cases. The overall success rate was 87.5%. Among the 7 patients who completed antibiotic treatment, the success rate was 100%. The clindamycin-rifampicin combination appeared to be effective in patients with C. perfringens BJI.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bone infection; Clindamycin-rifampicin; Clostridium perfringens; Metronidazole

Mesh:

Substances:

Year:  2021        PMID: 33723737     DOI: 10.1007/s10096-021-04225-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  1 in total

Review 1.  Therapeutic uses of metronidazole and its side effects: an update.

Authors:  A Hernández Ceruelos; L C Romero-Quezada; J C Ruvalcaba Ledezma; L López Contreras
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-01       Impact factor: 3.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.